Skip to main content

MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research

MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers efficiently identify and characterize plasmids.

Shirley, New York, United States - January 20, 2023 /MarketersMEDIA/

MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a renowned reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers to efficiently identify and characterize plasmids.

Plasmids are important carriers for the rapid adaptation of microbial populations to environmental changes, and plasmid-mediated gene transfer is critical for the spread of Antibiotic Resistance Genes (ARGs). Plasmids are transmissible between host cells, leading to the rapid dissemination of their accessory genes through bacterial communities. The Food Safety Authority (EFSA or FDA) requires critical plasmid information for the food or feed industry, mainly because of the spread of antibiotic resistance traits. CD Genomics has developed a unique sequencing-based platform to help researchers rapidly and effectively identify and characterize plasmids.

Plasmid-mediated horizontal gene transfer is considered a major driver of rapid adaptation and diversification in bacteria. Although the identification of unknown plasmids has been difficult due to the presence of repetitive sequences, CD Genomics has successfully employed next-generation sequencing (NGS) or long-read sequencing technologies to accurately capture all genomic knowledge of plasmids. “Combined with powerful bioinformatics algorithms and tools, we can help you identify antibiotic resistance genes, mobile genetic elements, and any other genetic information of interest,” commented the chief scientist of CD Genomics.

NGS and long-read sequencing technologies offer the powerful potential for plasmid identification, as well as diversity, characterization, and evolution studies. Not to mention long-read sequencing can span complex and repetitive regions, ensuring complete and accurate sequence data. Based on the Illumina HiSeq, PacBio, and Oxford nanopore sequencing platforms, CD Genomics is committed to providing full-length plasmid sequencing services to detect and identify plasmids.

“We help you discover mobile genetic elements, screen ARGs and annotate other accessory genes. Good annotation of plasmid genomes is necessary to maximize the value of the extended number of bacterial strains. Meanwhile, this information is key to determining food safety and quality and controlling antimicrobial resistance,” he further added.

Advantages of CD Genomics’ full-length plasmid sequencing services:

1. Standardized laboratory methods and quality assurance processes

2. Cutting-edge technologies for microbial genomics and bioinformatics analysis

3. Advanced genomics solutions and genome-based analysis

4. Next-generation sequencing and long-read sequencing platforms available

About the MicrobioSeq Division of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, a genomics service company with a renowned reputation for providing reliable microbial products, microbial testing services, microbial genomics services, and integrated bioinformatics services.

Contact Info:
Name: Kiko Garcia
Email: Send Email
Organization: CD Genomics
Website: https://www.cd-genomics.com/

Release ID: 89088538

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.